JP2018522891A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522891A5
JP2018522891A5 JP2018503215A JP2018503215A JP2018522891A5 JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5 JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018503215 A JP2018503215 A JP 2018503215A JP 2018522891 A5 JP2018522891 A5 JP 2018522891A5
Authority
JP
Japan
Prior art keywords
brain injury
traumatic brain
pharmaceutical composition
peptides
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/054318 external-priority patent/WO2017013599A1/en
Publication of JP2018522891A publication Critical patent/JP2018522891A/ja
Publication of JP2018522891A5 publication Critical patent/JP2018522891A5/ja
Priority to JP2022079211A priority Critical patent/JP2022113682A/ja
Pending legal-status Critical Current

Links

JP2018503215A 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法 Pending JP2018522891A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022079211A JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195183P 2015-07-21 2015-07-21
US62/195,183 2015-07-21
US201662288813P 2016-01-29 2016-01-29
US62/288,813 2016-01-29
PCT/IB2016/054318 WO2017013599A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022079211A Division JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Publications (2)

Publication Number Publication Date
JP2018522891A JP2018522891A (ja) 2018-08-16
JP2018522891A5 true JP2018522891A5 (https=) 2019-08-15

Family

ID=56550266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503215A Pending JP2018522891A (ja) 2015-07-21 2016-07-20 凝集ペプチドを標的とする外傷性脳損傷の治療方法
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022079211A Pending JP2022113682A (ja) 2015-07-21 2022-05-13 凝集ペプチドを標的とする外傷性脳損傷の治療方法

Country Status (7)

Country Link
US (1) US11327080B2 (https=)
EP (1) EP3325506A1 (https=)
JP (2) JP2018522891A (https=)
CN (1) CN107849125A (https=)
AU (1) AU2016295650A1 (https=)
CA (1) CA2991856A1 (https=)
WO (1) WO2017013599A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006069081A2 (en) * 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
RU2429244C2 (ru) * 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
PT2448968T (pt) 2009-06-29 2021-04-30 Bioarctic Ab ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
US10266585B2 (en) * 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
MX346500B (es) * 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN105979962A (zh) * 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies

Similar Documents

Publication Publication Date Title
JP2018522891A5 (https=)
Baron et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy
Jin et al. Minocycline improves postoperative cognitive impairment in aged mice by inhibiting astrocytic activation
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
FI3849534T3 (fi) Yhdistelmähoidot
JP2014530226A5 (https=)
BR112016020919A2 (pt) redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
JP2017149726A5 (https=)
Wang et al. Age-associated dopaminergic neuron loss and midbrain glia cell phenotypic polarization
WO2008050329A3 (en) Novel sirnas and methods of use thereof
HK1222297A1 (zh) 一种包含ampk激活剂及血清素活性制剂之医药组合物及其用途
JP2014518275A5 (https=)
Lee et al. Effect of a selective mas receptor agonist in cerebral ischemia in vitro and in vivo
JP2016512817A5 (https=)
JP2016539125A5 (https=)
Alme et al. Fingolimod does not enhance cerebellar remyelination in the cuprizone model
JP2016507547A5 (https=)
RU2010142456A (ru) Синергические комбинации 5'-метилтиоаденозина
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
ATE482711T1 (de) Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika
JP2016527312A5 (ja) ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
Mandal et al. Efficacy of prophylactic use of ciprofloxacin and metronidazole in mild and moderately severe acute pancreatitis.
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "
JP2017537083A5 (https=)